HealthyEarly Phase 1NCT03929250

Pharmacokinetics of Centella Asiatica in the Elderly

A Early Phase 1 study testing 2g Centella asiatica water extract product and 4g Centella asiatica water extract product in people with Healthy and Elderly, run by Oregon Health and Science University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

This study will measure the oral bioavailability and pharmacokinetics of known bioactive compounds from a standardized Centella asiatica water extract (CAW) product (CAP) in cognitively healthy elders. Read more about this study

Who is it for?: Ages 65 to 85 yearsHealthy volunteers can take part
Conditions the study is for: Healthy, Elderly
What is being tested?: 2g Centella asiatica water extract product and 4g Centella asiatica water extract product
Type of treatment: Pill or oral medicine
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 8 participants
Where: 1 siteUnited States
Study dates: 5 Jul 2019to 3 Jan 2024
Phase: Early Phase 1
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 65 to 85 years
All sexes
Healthy volunteers accepted
Older adult

Who may be able to join

Age 65-85, male and female
Sufficient English language skills to complete all tests
Sufficient vision and hearing to complete all tests
No known allergies to Centella asiatica or CAP components
Willingness to discontinue all botanical dietary supplements for one week prior to and during each study visit
Willingness to comply with a 48-hour low plant diet for each study visit

Show all 10Show fewer

Absence of significant depression symptoms (Geriatric Depression Scale-15 score of <12)
Body Mass Index (BMI) greater than 17 and less than 35 at screening
Non-demented, defined as Clinical Dementia Rating (CDR) score of zero and Mini Mental State Examination (MMSE) score >28
General health status that will not interfere with the ability to complete the study

Who cannot join

Current smoking, alcohol or substance abuse according to DSM-V criteria
Women who are pregnant, planning to become pregnant or breastfeeding
Men who are actively trying to conceive a child or planning to within three months of study completion
Severe aversion to venipuncture
Abnormal laboratory evaluation indicating asymptomatic and untreated urinary tract infection
Cancer within the last five years, with the exception of localized prostate cancer (Gleason Grade <3) and non-metastatic skin cancers

Show all 12Show fewer

Comorbid conditions such as diabetes mellitus, kidney failure, liver failure, hepatitis, blood disorders, clinical symptomatic orthostatic hypotension, and unstable or significantly symptomatic cardiovascular disease
Significant disease of the central nervous system such as brain tumor, seizure disorder, subdural hematoma, cranial arteritis, or clinically significant stroke
Major depression, schizophrenia, or other major psychiatric disorder defined by DSM-V criteria
Medications: sedatives (except those used occasionally for sleep), central nervous system active medications that have not been stable for two months (including beta blockers, cimetidine, SSRIs, SNRIs), anticoagulants (i.e. Warfarin), investigational drugs used within five half-lives of baseline visit, systemic corticosteroids, neuroleptics, anti-Parkinsonian agents, narcotic analgesics, nicotine (tobacco, patches, gum, lozenges, etc.), Cannabis sativa (herb or edibles)
Diseases associated with dementia such as Alzheimer's disease, vascular dementia, normal pressure hydrocephalus or Parkinson's disease with a CDR score >0.5 and MMSE score <28
Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements

Trial locations and contacts

1 site in 1 country.

United States1 site

Oregon Health and Science University Department of Neurology
Portland, Oregon, 97239

Other trials in United States

About this study

Official title: A Pharmacokinetic Study of Centella Asiatica in the Elderly

Read the detailed description

PRIMARY OBJECTIVES:

To assess the bioavailability and rate of clearance of Centella asiatica derived compounds in the plasma and urine of cognitively healthy elders over 12 hours.
To determine the acute tolerability of a Centella asiatica product in cognitively healthy elders.

OUTLINE:

Participants will orally consume a single administration of a standardized Centella asiatica water extract product (CAP). Two doses (2g and 4g CAW) will be administered on separate occasions, at least two weeks apart. The levels of known bioactive compounds present in Centella asiatica will be measured in human plasma and urine over 12 hours after administration of each of the doses.

Conditions: Healthy, Elderly
Being tested: 2g Centella asiatica water extract product, 4g Centella asiatica water extract product

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

2g Centella asiatica water extract productDrug
Also called CAP 2g
2g Centella asiatica water extract product is a powder containing Centella asiatica water extract (CAW) and excipients to improve palatability, color matching and dispersability in water. It will be consumed on an empty stomach orally suspended in 10-12 ounces of water.
4g Centella asiatica water extract productDrug
Also called CAP 4g
4g Centella asiatica water extract product is a powder containing Centella asiatica water extract (CAW) and excipients to improve palatability, color matching and dispersability in water. It will be consumed on an empty stomach orally suspended in 10-12 ounces of water.

Study groups in NCT03929250
Study group	Role	What they receive
2g CAW Dose, then 4g CAW Dose	Experimental	Participants first receive a single dose of a product containing 2g CAW, then after a minimum washout period of 2 weeks, they receive a single dose of a product containing 4g CAW. Receives: Drug: 2g Centella asiatica water extract product; Drug: 4g Centella asiatica water extract product
4g CAW Dose, then 2g CAW Dose	Experimental	Participants first receive a single dose of a product containing 4g CAW, then after a minimum washout period of 2 weeks, they receive a single dose of a product containing 2g CAW. Receives: Drug: 2g Centella asiatica water extract product; Drug: 4g Centella asiatica water extract product

What is being measured

The primary outcome is the main question the study is designed to answer.

Maximum Human Plasma Concentration of Bioactives From Centella Asiatica.
Following oral administration of a product made from a water extract of Centella asiatica (CAP), the plasma concentration of Centella asiatica derived bioactive compounds (triterpenes, caffeoylquinic acids, and their metabolites) will be measured in blood samples obtained over a 12 hour period, using high performance liquid chromatography tandem mass spectrometry in order to generate a pharmacokinetic curve, and determine pharmacokinetic parameters (maximum concentration and area under the curve) for each of the two doses (2g and 4g).
Measured: A 12-hour post-administration period (15, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes).
Total Plasma Concentration Over Time (Area Under the Curve) From Centella Asiatica Water Extract Product.
Following oral administration of a product made from a water extract of Centella asiatica (CAP), the plasma concentration of Centella asiatica derived bioactive compounds (triterpenes, caffeoylquinic acids, and their metabolites) will be measured in blood samples obtained over a 12 hour period, using high performance liquid chromatography tandem mass spectrometry in order to generate a pharmacokinetic curve, and determine pharmacokinetic parameters (maximum concentration and area under the curve) for each of the two doses (2g and 4g).
Measured: A 12-hour post-administration period (15, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes).
Half-life
The half-life (t1/2) of the known bioactive compounds was calculated from the plasma concentrations measured by high performance liquid chromatography tandem mass spectrometry to help determine dosage intervals.
Measured: A 12-hour post-administration period (15, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes).
Time of Maximum Concentration
The time of maximum concentration (tmax) of the known bioactive compounds and their metabolites will be calculated from the concentrations measured by high performance liquid chromatography tandem mass spectrometry in order to help determine dosage intervals
Measured: A 12-hour post-administration period (15, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes).

Secondary outcomes (7)

Urinary Excretion
The concentration of bioactive compounds from Centella asiatica (triterpenes, caffeoylquinic acids, and their metabolites) will be measured in a pooled urine sample collected over 12 hours after CAP administration and analyzed using high performance liquid chromatography tandem mass spectrometry.
Measured: Over 12 hours post-administration
Oral Temperature
Oral temperature will be measured in degrees Fahrenheit by means of a thermometer.
Measured: 720 minutes after administration
Pulse Rate
Pulse rate will be measured peripherally over one minute.
Measured: 720 minutes after administration
Seated Systolic Blood Pressure
Seated blood pressure will be measured in millimeters mercury.
Measured: 720 minutes after administration
Body Mass Index
Height in centimeters and weight in kilograms will be measured and aggregated to measure body mass index in kilograms per meter squared (kg/m2).
Measured: 720 minutes after administration
Participants With Change in Electrocardiography
Resting electrocardiography will be measured for up to five minutes using a five lead mobile electrocardiogram. The investigators will determine the number of participants who develop changes in electrocardiography compared to the zero minute timepoint following CAP administration.
Measured: 0, 360 and 720 minutes after administration
Seated Diastolic Blood Pressure
Seated blood pressure will be measured in millimeters mercury.
Measured: 720 minutes after administration

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

5 Jul 20193 Jan 2024

First posted26 Apr 2019
Study start5 Jul 2019
Primary completion30 Nov 2019
Study completion3 Jan 2024

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for HealthyStudies of the same condition, open and under way.
More trials run by Oregon Health and Science UniversityThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Early Phase 1
Primary purpose: Screening
Allocation: Randomised
Intervention model: Crossover
Model description: Randomization will use an arm equivalence design to promote equal numbers of participants for each order schema.
Masking: Double blind
Who is masked: Participant, Outcomes assessor
Enrolment: 8 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT03929250
Sponsor's protocol ID: STUDY00017697
Status last verified: Jul 2025
First submitted: 21 Apr 2019
Last updated: 6 Aug 2025
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: Yes
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: Yes: All IPD that underlie results reported in a publication after de-identification.

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis

All Healthy trials

Study at a glance

From the registry record, last updated by the sponsor on 6 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Pharmacokinetic Study of Centella Asiatica in the Elderly
ClinicalTrials.gov ID: NCT03929250
Acronym / sponsor ID: STUDY00017697
Conditions: Healthy, Elderly
Phase: Early Phase 1
Study type: Interventional
Recruitment status: Completed
Enrolment: 8 participants (actual)
Lead sponsor: Oregon Health and Science UniversityUniversity, hospital or other
Study start: 5 Jul 2019 (actual)
Primary completion: 30 Nov 2019 (actual)
Study completion: 3 Jan 2024 (actual)
First posted: 26 Apr 2019 (actual)
Results: Posted 6 Aug 2025

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

PRIMARY OBJECTIVES:

To assess the bioavailability and rate of clearance of Centella asiatica derived compounds in the plasma and urine of cognitively healthy elders over 12 hours.
To determine the acute tolerability of a Centella asiatica product in cognitively healthy elders.

OUTLINE:

Study design

Primary purpose: Screening
Allocation: Randomised
Intervention model: Crossover
Masking: Double blind (participant, outcomes assessor)
Number of arms: 2
Model description: Randomization will use an arm equivalence design to promote equal numbers of participants for each order schema.

Arm	Type	Receives
2g CAW Dose, then 4g CAW Dose	Experimental	Drug: 2g Centella asiatica water extract product, Drug: 4g Centella asiatica water extract productParticipants first receive a single dose of a product containing 2g CAW, then after a minimum washout period of 2 weeks, they receive a single dose of a product containing 4g CAW.
4g CAW Dose, then 2g CAW Dose	Experimental	Drug: 2g Centella asiatica water extract product, Drug: 4g Centella asiatica water extract productParticipants first receive a single dose of a product containing 4g CAW, then after a minimum washout period of 2 weeks, they receive a single dose of a product containing 2g CAW.

Who may qualify

Ages: 65 to 85 years
Sex: All
Healthy volunteers: Accepted
Age groups: Older adult

Key inclusion criteria (10 listed)

Age 65-85, male and female
Sufficient English language skills to complete all tests
Sufficient vision and hearing to complete all tests
No known allergies to Centella asiatica or CAP components
Willingness to discontinue all botanical dietary supplements for one week prior to and during each study visit

Key exclusion criteria (12 listed)

Current smoking, alcohol or substance abuse according to DSM-V criteria
Women who are pregnant, planning to become pregnant or breastfeeding
Men who are actively trying to conceive a child or planning to within three months of study completion
Severe aversion to venipuncture
Abnormal laboratory evaluation indicating asymptomatic and untreated urinary tract infection

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
2g Centella asiatica water extract productAlso: CAP 2g2g Centella asiatica water extract product is a powder containing Centella asiatica water extract (CAW) and excipients to improve palatability, color matching and dispersability in water. It will be consumed on an empty stomach orally suspended in 10-12 ounces of water.	Drug	2g CAW Dose, then 4g CAW Dose, 4g CAW Dose, then 2g CAW Dose
4g Centella asiatica water extract productAlso: CAP 4g4g Centella asiatica water extract product is a powder containing Centella asiatica water extract (CAW) and excipients to improve palatability, color matching and dispersability in water. It will be consumed on an empty stomach orally suspended in 10-12 ounces of water.	Drug	2g CAW Dose, then 4g CAW Dose, 4g CAW Dose, then 2g CAW Dose

Primary outcome

Maximum Human Plasma Concentration of Bioactives From Centella Asiatica.
Time frame: A 12-hour post-administration period (15, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes).
Following oral administration of a product made from a water extract of Centella asiatica (CAP), the plasma concentration of Centella asiatica derived bioactive compounds (triterpenes, caffeoylquinic acids, and their metabolites) will be measured in blood samples obtained over a 12 hour period, using high performance liquid chromatography tandem mass spectrometry in order to generate a pharmacokinetic curve, and determine pharmacokinetic parameters (maximum concentration and area under the curve) for each of the two doses (2g and 4g).
Total Plasma Concentration Over Time (Area Under the Curve) From Centella Asiatica Water Extract Product.
Time frame: A 12-hour post-administration period (15, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes).
Following oral administration of a product made from a water extract of Centella asiatica (CAP), the plasma concentration of Centella asiatica derived bioactive compounds (triterpenes, caffeoylquinic acids, and their metabolites) will be measured in blood samples obtained over a 12 hour period, using high performance liquid chromatography tandem mass spectrometry in order to generate a pharmacokinetic curve, and determine pharmacokinetic parameters (maximum concentration and area under the curve) for each of the two doses (2g and 4g).
Half-life
Time frame: A 12-hour post-administration period (15, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes).
The half-life (t1/2) of the known bioactive compounds was calculated from the plasma concentrations measured by high performance liquid chromatography tandem mass spectrometry to help determine dosage intervals.
Time of Maximum Concentration
Time frame: A 12-hour post-administration period (15, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes).
The time of maximum concentration (tmax) of the known bioactive compounds and their metabolites will be calculated from the concentrations measured by high performance liquid chromatography tandem mass spectrometry in order to help determine dosage intervals

7 secondary outcomes

Urinary Excretion
Time frame: Over 12 hours post-administration
Oral Temperature
Time frame: 720 minutes after administration
Pulse Rate
Time frame: 720 minutes after administration
Seated Systolic Blood Pressure
Time frame: 720 minutes after administration
Body Mass Index
Time frame: 720 minutes after administration
Participants With Change in Electrocardiography
Time frame: 0, 360 and 720 minutes after administration
Seated Diastolic Blood Pressure
Time frame: 720 minutes after administration

Results and safety

Results posted to the registry on 6 Aug 2025, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
2g CAW Dose, Then 4g CAW Dose	4	4
4g CAW Dose, Then 2g CAW Dose	4	3

Primary outcome: Maximum Human Plasma Concentration of Bioactives From Centella Asiatica.

Time frame: A 12-hour post-administration period (15, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes).. Mean (Standard Error). Unit: ng/mL

Measure	2g CAW Dose n = 7	4g CAW Dose n = 8
Asiatic acid	174 (22)	372 (53)
Caffeic acid	0.3 (0.1)	0.5 (0.1)
Dihydrocaffeic acid	0.4 (0.1)	0.5 (0.1)
Dihydroferulic acid	9.3 (4.4)	8.1 (2.9)
Dicaffeoylquinic acids	1.2 (0.6)	1.9 (0.8)
Ferulic acid	1.5 (0.3)	1.5 (0.6)
3-(3-hydroxyphenyl)propionic acid	5.8 (3.0)	10.6 (2.9)
Isoferulic acid	1.5 (0.8)	1.5 (0.4)

Primary outcome: Total Plasma Concentration Over Time (Area Under the Curve) From Centella Asiatica Water Extract Product.

Time frame: A 12-hour post-administration period (15, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes).. Mean (Standard Error). Unit: ng/mL*hr

Measure	2g CAW Dose n = 7	4g CAW Dose n = 8
Asiatic acid	48755 (7152)	91330 (17723)
Caffeic acid	1.8 (0.5)	2.4 (0.6)
Dihydrocaffeic acid	1.7 (0.6)	1.9 (0.5)
Dihydroferulic acid	35.6 (18.6)	41.0 (12.7)
Dicaffeoylquinic acids	3.4 (1.8)	5.0 (1.5)
Ferulic acid	11.3 (2.9)	9.9 (2.8)
3-(3-hydroxyphenyl)propionic acid	56.8 (31.7)	50.2 (15.1)
Isoferulic acid	5.3 (1.6)	7.4 (1.6)

Primary outcome: Half-life

Time frame: A 12-hour post-administration period (15, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes).. Mean (Standard Error). Unit: hours

Measure	2g CAW Dose n = 7	4g CAW Dose n = 8
Asiatic acid	4.1 (0.7)	4.9 (1.3)
Caffeic acid	8.4 (3)	10.3 (3.7)
Dihydrocaffeic acid	1.8 (1.2)	1.9 (0.8)
Dihydroferulic acid	7.1 (1.7)	6.6 (3.8)
Dicaffeoylquinic acids	2 (1.2)	2.6 (1.8)
Ferulic acid	14.1 (3.9)	2.9 (1.3)
3-(3-hydroxyphenyl)propionic acid	5 (2)	2.6 (0.5)
Isoferulic acid	7 (2.4)	3.5 (0.5)

Primary outcome: Time of Maximum Concentration

Time frame: A 12-hour post-administration period (15, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes).. Mean (Standard Error). Unit: hours

Measure	2g CAW Dose n = 7	4g CAW Dose n = 8
Asiatic acid	2.2 (0.4)	2.8 (0.2)
Caffeic acid	5.3 (1.9)	4.5 (1.6)
Dihydrocaffeic acid	6.1 (1.7)	3.2 (1.3)
Dihydroferulic acid	5.9 (1.6)	5.7 (1.5)
Dicaffeoylquinic acids	3.7 (1.9)	4.3 (1.7)
Ferulic acid	5.9 (1.3)	7.1 (1.2)
3-(3-hydroxyphenyl)propionic acid	7.4 (1.5)	5.7 (0.7)
Isoferulic acid	2.4 (1)	1 (0.32)

7 secondary outcomes are reported in the full results.

Adverse events

Time frame: 0, 6, 12 and 24 hours after administration of each dose level (2g CAW or 4g CAW). Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
2g CAW Dose	0 of 8 (0%)	4 of 8 (50%)	0 of 8
4g CAW Dose	0 of 8 (0%)	4 of 8 (50%)	0 of 8

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 6 Aug 2025.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Individual participant dataSharing planned: Yes. All IPD that underlie results reported in a publication after de-identification.

Related trials for Healthy

Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Amala Soumyanath, PhD principal investigator

OHSU Department of Neurology

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 6 Aug 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Maximum Human Plasma Concentration of Bioactives From Centella Asiatica. (time frame: A 12-hour post-administration period (15, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes).). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03929250.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2025.